- Home
- AIO vs ACRS Comparison
AIO vs ACRS Comparison
Compare AIO & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AIO | ACRS |
|---|---|---|
| Founded | 2019 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 927.8M | 868.5M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | AIO | ACRS |
|---|---|---|
| Price | $26.67 | $5.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $10.20 |
| AVG Volume (30 Days) | 71.8K | ★ 1.8M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 9.05% | N/A |
| EPS Growth | N/A | ★ 69.01 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,683,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.91 | $1.70 |
| 52 Week High | $28.60 | $6.52 |
Technical Indicators
Market Signals| Indicator | AIO | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 57.68 | 56.88 |
| Support Level | $25.05 | $4.13 |
| Resistance Level | $26.67 | $6.52 |
| Average True Range (ATR) | 0.51 | 0.37 |
| MACD | 0.18 | 0.01 |
| Stochastic Oscillator | 93.17 | 57.14 |
Price Performance
Historical ComparisonAbout AIO Virtus Artificial Intelligence & Technology Opportunities Fund of Beneficial Interest
Virtus Artificial Intelligence & Technology Opportunities Fund is a diversified, limited-term, closed-end management investment company. Its investment objective is to provide total return through a combination of current income, current gains, and long-term capital appreciation.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.